Onvatilimab

Onvatilimab Suppliers list
Company Name: Aladdin Scientific
Tel: +1-+1(833)-552-7181
Email: sales@aladdinsci.com
Products Intro: Product Name:Onvatilimab (anti-VISTA)
CAS:1969313-51-6
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:$59.9/100μg;$297.9/1mg;$837.9/5mg;$1227.9/10mg;Bulk package Remarks:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 17754423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Onvatilimab
CAS:1969313-51-6
Purity:95% Package:100ug;500ug;1mg
Company Name: Guangzhou Hongyuan Chemical Co.,Ltd  
Tel: 15817493340
Email: 981810490@qq.com
Products Intro: Product Name:Onvatilimab
CAS:1969313-51-6
Purity:95% Package:1mg;1g;100g
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Onvatilimab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310
Email: marketing@tsbiochem.com
Products Intro: Product Name:Onvatilimab
CAS:1969313-51-6
Purity:SDS-PAGE:95% SEC-HPLC:98.11% Package:1mg/RMB 2480;5mg/RMB 5860;10mg/RMB 7890
Onvatilimab Basic information
Product Name:Onvatilimab
Synonyms:Onvatilimab;Research Grade Onvatilimab(DHK06901);Onvatilimab (anti-VISTA);JNJ-61610588
CAS:1969313-51-6
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Onvatilimab Structure
Onvatilimab Chemical Properties
storage temp. Store at -20°C
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Onvatilimab Usage And Synthesis
UsesOnvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity.
Onvatilimab Preparation Products And Raw materials
Tag:Onvatilimab(1969313-51-6) Related Product Information
Sabatolimab Unii-fys6T7F842 Certolizumab Bevacizumab belimumab Aflibercept Tiragolumab Ranibizumab palivizumab Infliximab